CCCC logo

C4 Therapeutics (CCCC) EBIT

Annual EBIT

-$129.84 M
-$3.88 M-3.08%

31 December 2023

CCCC EBIT Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly EBIT

-$24.67 M
-$6.95 M-39.23%

30 September 2024

CCCC Quarterly EBIT Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM EBIT

-$105.22 M
+$1.20 M+1.13%

30 September 2024

CCCC TTM EBIT Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

CCCC EBIT Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-3.1%+4.6%+20.3%
3 y3 years-97.5%-2.2%-19.6%
5 y5 years-692.2%-146.6%-952.1%

CCCC EBIT High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 years-97.5%at low-63.1%+32.6%-28.7%+23.5%
5 y5 years-692.2%at low-195.7%+32.6%-952.1%+23.5%
alltimeall time-692.2%at low-195.7%+32.6%-952.1%+23.5%

C4 Therapeutics EBIT History

DateAnnualQuarterlyTTM
Sept 2024
-
-$24.67 M(+39.2%)
-$105.22 M(-1.1%)
June 2024
-
-$17.72 M(-37.5%)
-$106.42 M(-14.2%)
Mar 2024
-
-$28.36 M(-17.7%)
-$124.03 M(-4.5%)
Dec 2023
-$129.84 M(+3.1%)
-$34.48 M(+33.3%)
-$129.84 M(-1.6%)
Sept 2023
-
-$25.87 M(-26.8%)
-$131.95 M(-4.0%)
June 2023
-
-$35.32 M(+3.4%)
-$137.48 M(+6.5%)
Mar 2023
-
-$34.17 M(-6.6%)
-$129.04 M(+2.4%)
Dec 2022
-$125.96 M(+54.1%)
-$36.58 M(+16.5%)
-$125.96 M(+20.5%)
Sept 2022
-
-$31.40 M(+16.8%)
-$104.49 M(+7.5%)
June 2022
-
-$26.88 M(-13.6%)
-$97.23 M(+5.2%)
Mar 2022
-
-$31.09 M(+105.7%)
-$92.40 M(+13.0%)
DateAnnualQuarterlyTTM
Dec 2021
-$81.75 M(+24.4%)
-$15.12 M(-37.4%)
-$81.75 M(-7.1%)
Sept 2021
-
-$24.14 M(+9.5%)
-$88.01 M(+3.2%)
June 2021
-
-$22.05 M(+7.9%)
-$85.30 M(+15.1%)
Mar 2021
-
-$20.44 M(-4.4%)
-$74.09 M(+12.7%)
Dec 2020
-$65.73 M(+97.4%)
-$21.38 M(-0.3%)
-$65.73 M(+24.7%)
Sept 2020
-
-$21.44 M(+97.9%)
-$52.70 M(+27.7%)
June 2020
-
-$10.83 M(-10.3%)
-$41.26 M(+35.6%)
Mar 2020
-
-$12.08 M(+44.8%)
-$30.42 M(+65.9%)
Dec 2019
-$33.30 M(+103.2%)
-$8.34 M(-16.6%)
-$18.34 M(+83.4%)
Sept 2019
-
-$10.00 M
-$10.00 M
Dec 2018
-$16.39 M
-
-

FAQ

  • What is C4 Therapeutics annual earnings before interest & taxes?
  • What is the all time high annual EBIT for C4 Therapeutics?
  • What is C4 Therapeutics annual EBIT year-on-year change?
  • What is C4 Therapeutics quarterly earnings before interest & taxes?
  • What is the all time high quarterly EBIT for C4 Therapeutics?
  • What is C4 Therapeutics quarterly EBIT year-on-year change?
  • What is C4 Therapeutics TTM earnings before interest & taxes?
  • What is the all time high TTM EBIT for C4 Therapeutics?
  • What is C4 Therapeutics TTM EBIT year-on-year change?

What is C4 Therapeutics annual earnings before interest & taxes?

The current annual EBIT of CCCC is -$129.84 M

What is the all time high annual EBIT for C4 Therapeutics?

C4 Therapeutics all-time high annual earnings before interest & taxes is -$15.12 M

What is C4 Therapeutics annual EBIT year-on-year change?

Over the past year, CCCC annual earnings before interest & taxes has changed by -$3.88 M (-3.08%)

What is C4 Therapeutics quarterly earnings before interest & taxes?

The current quarterly EBIT of CCCC is -$24.67 M

What is the all time high quarterly EBIT for C4 Therapeutics?

C4 Therapeutics all-time high quarterly earnings before interest & taxes is -$8.34 M

What is C4 Therapeutics quarterly EBIT year-on-year change?

Over the past year, CCCC quarterly earnings before interest & taxes has changed by +$1.20 M (+4.64%)

What is C4 Therapeutics TTM earnings before interest & taxes?

The current TTM EBIT of CCCC is -$105.22 M

What is the all time high TTM EBIT for C4 Therapeutics?

C4 Therapeutics all-time high TTM earnings before interest & taxes is -$10.00 M

What is C4 Therapeutics TTM EBIT year-on-year change?

Over the past year, CCCC TTM earnings before interest & taxes has changed by +$26.73 M (+20.26%)